The disingenuous thing here is they are not “betting odds on cancer” The prediction markets are on the outcomes of clinical trial research. The main reason large Wall St firms don’t invest in clinical stage funding for new pharma companies is outcome risk when a trial fails. When they have markets to hedge that outcome as a binary swap, others firms can buy and underwrite that risk. Having a hedging option for this, means more investment flows into cancer research funding. People recoil at these markets by framing it as betting and assuming there is no benefit. They are complex and nuanced financial products. It does not matter if you like it. It fundamentally changes the economics around investing in cancer research. It makes it so MORE money can reliably reach more small pharma research companies. If you are trying to compare that to DraftKings to score political points about a boogeyman - then you’ve lost the plot.(Adam Cochran (adamscochran.eth))